Tag Archives: BIO Investor Forum

Fall Preview: Business Development Events

Banner

Now that the Business Forum and International Convention are behind us, our Business Development department has been gearing up for a very busy Fall schedule.   The Line-Up For our first Fall event, BIO returns to India for its 2nd annual BIO India International Partnering Conference September 21st and 22nd.  Last year’s conference attracted more than 400 attendees representing 220 companies, from 17 countries around the world, – who scheduled over 750 meetings.  We’ve had Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

State of the Industry – From BIO Investor Forum 2010

Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: BIO Investor Forum 2010 final   From the media and blogosphere: Bloomberg in vivo blog Medical Technology Stock Letter

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The booming H1N1 vaccine market

The vaccine market is booming – and biotech companies are just one of the beneficiaries.  A recent Associated Press Article explains that an increase in government support and newer, better technologies are just a part of it.  Patients look to benefit from new vaccinations on the horizon for diseases such as Alzheimer’s, herpes, malaria, and perhaps even a universal flu vaccine. It was just last month at the BIO Investor Forum’s H1N1 panel that panelists Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , ,

Perspectives on today’s IPO candidates

Some speculation is coming back into the sector but most movement in public markets is specialist driven, not generalist driven. What will it take to get the generalist investors in? Unfortunately, most IPO stocks since 2005 have underperformed and have left a bad taste in the mouths of generalists. This has left generalists believing they cannot just come into the sector and purchase a basket of young biotechs. Example of a successful IPO: Targacept filed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Panelists make it personal

Panelists in the “Making it Personal” session discussed the clinical utility, comparative effectiveness implications and reimbursement for personalized medicine. Tod Klinger, PhD of XDx, Inc. asserted that we are still in the early stages of personalized medicine since there is a need to determine how to link measurements with relevant clinical information for the patient to enable decision making. Furthermore, there are many other questions that still need to be considered. Ellen Sheets, MD, of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,